Robbins LLP Alerts IINO Stockholders of the Class Action Against Inovio Pharmaceuticals Inc.

Robbins LLP Alerts IINO Stockholders of Class Action

Robbins LLP has issued a reminder to all stockholders that a class action lawsuit has been filed concerning Inovio Pharmaceuticals, Inc. (NASDAQ: INO). This action affects individuals who acquired Inovio securities from October 10, 2023, through December 26, 2025. The case primarily revolves around allegations that Inovio misled its investors regarding crucial details about its CELLECTRA device.

Inovio is a biotechnology company engaged in developing DNA medicines aimed at treating diseases, including those linked to human papillomavirus (HPV). Throughout the class period, it has been alleged that the company failed to adequately disclose several key issues about its operations and regulatory compliance status, particularly relating to manufacturing shortcomings and hastily projected timelines for its products.

Allegations of Misleading Practices

According to legal complaints, Inovio's management did not reveal that the production processes for their CELLECTRA device were deficient. This oversight led to concerns that the company would not be able to submit the Biologics License Application (BLA) for INO-3107 to the FDA within the anticipated timeline. Ultimately, the company was found lacking vital information necessary to support a swift approval of the INO-3107 application.

The initial accusations came to light on August 8, 2024, when Inovio disclosed that it anticipated a delay in submitting the BLA until mid-2025. This press release sent shockwaves through the investor community, resulting in a notable drop of 3.1% in Inovio’s stock price, closing at $8.44 the following day.

Further compounding these issues, on December 29, 2025, Inovio announced that the FDA would review the INO-3107 BLA under standard timelines rather than the expedited approval process that had been expected. This revelation led to a dramatic stock price drop of 24.45%, plummeting to $1.73.

Investor Participation in the Class Action

Investors who were affected by these developments may be eligible to participate in the ongoing class action against Inovio. Those wishing to step into the role of lead plaintiff must submit their documents to the court by April 7, 2026, which allows for direct leadership in this litigation process. It is noteworthy, however, that participating in the case is not a requisite for potential recovery; investors can opt to remain absent from the proceedings.

Robbins LLP operates on a contingency fee basis, meaning shareholders will incur no fees unless a recovery is obtained.

About Robbins LLP

Since 2002, Robbins LLP has established itself as a leader in the field of shareholder rights litigation. The firm is committed to ensuring that shareholders reclaim their losses, enhance governance frameworks, and hold corporate officers accountable for wrongdoing. As part of their services, interested parties are encouraged to sign up for Stock Watch alerts which will notify them of developments such as potential settlements related to class actions.

In conclusion, stockholders of Inovio Pharmaceuticals should remain vigilant regarding updates on the progress of this class action, as it could have significant implications for current and future investments.